A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine

A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Immunogenicity of a 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Pichia Pastoris) in 9 to 45 Year Old Chinese Females

A randomized, double-blind and placebo-controlled phase I study to evaluate the safety and immunogenicity of a 9-valent Human Papillomavirus (HPV) vaccine, administered intramuscularly according to a 0, 2, 6-month schedule in 9 to 45 years old healthy Chinese females.

Study Overview

• Status: Completed
• Conditions: HPV Infections
• Intervention / Treatment: Biological: HPV Vaccine; Drug: Placebo

• Study Type: Interventional
• Enrollment (Actual): 90
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Xuecheng LIU, BS; Phone Number: +8618981958206; Email: 534210793@qq.com

Study Locations

• China
  • Sichuan
    • Chengdu, Sichuan, China, 610041
      • Sichuan Provincial Center for Disease Prevention and Control

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 7 years to 43 years (Child, Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Healthy females, 9 to 45 years old (inclusive).
• 9 to 17 years old participants: able to prove their identities and provide their legal guardians' identity information.
• Legal guardians of the 9 to 17 years old participants: able to understand (not illiterate) and agree to co-sign the informed consent forms with participants
• 18 to 45 years old participants: able to prove their legal identities.
• 18 to 45 years old participants: able to understand (not illiterate) the study and agree to sign the informed consent form.
• Child bearing age participants: agree not to become pregnant by using proper contraception means in the 7-month study period.

Exclusion Criteria:

• History of cervical cancer or genital warts.
• History HPV vaccination or history of participation in HPV vaccine trial.
• History of severe allergy which needs medical intervention such as swelling of the mouth and throat, difficulty breathing, hypotension or shock.
• Skin abnormality at injection site including inflammation, sclerosis, redness, swelling, and extensive scars.
• History of allergy to vaccine or vaccine components including aluminum phosphate, histidine and Polysorbate 80, and severe adverse reactions in past vaccination.
• Medical history of epilepsy, convulsions, seizures , or family history of mental illness.
• Medical conditions including immunocompromised or diagnosed as congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease or other autoimmune diseases and received immunosuppressants in 6 months prior to first vaccination.
• History of asthma, thyroidectomy, angioneurotic edema, diabetes, and malignancy.
• Asplenia, functional asplenia, or any circumstances as a result of asplenia or splenectomy
• Diagnosis as coagulation abnormalities such as clotting factor deficiency, platelet abnormalities or having significant bruising, or coagulation disorder
• Being diagnosed with acute illnesses or acute onset of chronic illness during the last 3 days.
• Treatment with immunoglobulins or other blood-derived products within 3 months prior to Day 0 vaccination.
• Having received subunit or inactivated vaccine within 14 days prior to Day 0 vaccination or received attenuated vaccine within 28 days prior to Day 0 vaccination.
• Fever before vaccine administration with axillary temperature higher than 37.0°C.
• Currently breastfeeding, and being pregnant including pregnancy test positive.
• History of hypertension: Participants of 13 to 45 years of age have their respective systolic blood pressure greater than 150 mmHg and/or diastolic blood pressure greater than 100 mmHg; or participants of 9 to 12 years of age demonstrate their respective systolic blood pressure higher than 120 mmHg and/or diastolic blood pressure higher than 80 mmHg.
• Exhibits of abnormal lab test parameters.
• Any other factors which might affect any individual to be enrolled in the study according to the investigator's judgment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: HPV vaccine; Subjects receive 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.	Biological: HPV Vaccine; Intramuscular injection, 3 doses
Placebo Comparator: Placebo; Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.	Drug: Placebo; Intramuscular injection, 3 doses

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Subjects Reporting Solicited Local Symptoms	Solicited local symptoms assessed including pain, redness, swelling, induration and itching.	During a 8-day period (Day 0-7) following each vaccination
Percentage of Subjects Reporting Solicited General Symptoms	Solicited general symptoms assessed including fever, headache, fatigue, nausea, diarrhea, vomiting, myalgia, allergic reaction	During a 8-day period (Day 0-7) following each vaccination
Percentage of Subjects Reporting Unsolicited Adverse Events (AEs)	An unsolicited adverse event is defined as any adverse event (AE) reported in addition to those solicited during the clinical study.	Within 31 days (Day 0-30) after any vaccination
Percentage of Subjects Reporting Serious Adverse Events (SAE)	Serious adverse events are defined as medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.	Throughout the study period (up to Month 12)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Seroconversion Percentages to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58	Seroconversion is defined as a participant who was anti-HPV seronegative at Day 0 (before vaccination) and became seropositive 30days after the third dose (Month 7).	30 days after the third dose (Month 7)
Geometric Mean Titers (GMT) of HPV serotype-specific antibody	HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 specific antibodies GMT	30 days after the third dose (Month 7)

Collaborators and Investigators

• Sponsor: Shanghai Zerun Biotechnology Co.,Ltd
• Investigators: Principal Investigator: Xuecheng LIU, BS, Sichuan Provincial Center for Disease Prevention and Control

Study record dates

Study Major Dates

• Study Start (Actual): March 9, 2019
• Primary Completion (Actual): April 30, 2020
• Study Completion (Actual): April 30, 2020

Study Registration Dates

• First Submitted: March 28, 2019
• First Submitted That Met QC Criteria: April 2, 2019
• First Posted (Actual): April 3, 2019

Study Record Updates

• Last Update Posted (Estimate): April 13, 2023
• Last Update Submitted That Met QC Criteria: April 12, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Keywords: Cervical Cancer; Human Papilloma Virus; Genital Warts; Papillomavirus vaccines
• Additional Relevant MeSH Terms: Virus Diseases; Infections; DNA Virus Infections; Tumor Virus Infections; Papillomavirus Infections
• Other Study ID Numbers: 312-HPV-2001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No